Allogene Therapeutics, Inc. (ALLO) Net margin 2021–2024
Allogene Therapeutics, Inc. (ALLO) net profit margin by fiscal year — reported net income divided by reported revenue.
-1170863.6%FY2024 · since FY2021: -159.6% → -1170863.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2024 | -1170863.6% | -826374.2 pp |
| FY2023 | -344489.5% | -126275.4 pp |
| FY2022 | -218214.1% | -218054.5 pp |
| FY2021 | -159.6% | — |
Net margin = reported net income ÷ reported revenue for the same fiscal year. Loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More ALLO financial trends
ALLO RevenueALLO Net incomeALLO Gross profitALLO Gross marginALLO Operating incomeALLO Operating marginALLO Operating cash flowALLO Free cash flowALLO Capital expendituresALLO Return on equityALLO Stock buybacksALLO Dividends paidALLO Total assetsALLO Total liabilitiesALLO Shareholders’ equityALLO overview →